Migraine Treatment Beyond Pills: How CGRP and PACAP Therapies Fit with Alternative Approaches
This review examines complementary and alternative therapies for migraine alongside emerging peptide-targeted treatments like CGRP and PACAP antagonists, offering a broader perspective on pain management options.
Quick Facts
What This Study Found
Complementary and alternative therapies (CAT) show varying levels of evidence for migraine management, while novel peptide-targeting therapies (CGRP antagonists and monoclonal antibodies, PACAP antagonists) represent the most significant pharmacological advance in migraine treatment. The review proposes that CAT may serve as adjunctive therapy alongside these new peptide-based treatments.
Key Numbers
Women are more susceptible to migraine. Long-term NSAID use is the main first-line approach but leads to side effects and drug adaptation.
How They Did This
Narrative review summarizing the pathophysiology of migraine, the mechanisms and evidence for various complementary and alternative therapies, and the potential of CGRP and PACAP antagonists as novel migraine treatments.
Why This Research Matters
Migraine treatment is being transformed by peptide-targeting drugs, but many patients also seek non-pharmacological options due to medication side effects or personal preference. Understanding how complementary therapies work alongside these new peptide-based drugs helps patients and clinicians design comprehensive, personalized treatment plans.
The Bigger Picture
The migraine treatment landscape is shifting from broad pain relievers to targeted peptide-based therapies. CGRP-targeting drugs (erenumab, galcanezumab, fremanezumab) have already transformed prevention, and PACAP antagonists are in development. Integrating these with evidence-based complementary approaches could optimize outcomes for the estimated 1 billion people worldwide affected by migraine.
What This Study Doesn't Tell Us
As a narrative review, it doesn't systematically assess quality of evidence for each therapy. Many complementary therapies have limited high-quality RCT data. The discussion of CGRP/PACAP therapies is not exhaustive. Potential publication bias in alternative medicine studies is not addressed.
Questions This Raises
- ?Can complementary therapies reduce the dose or frequency of CGRP-targeting drugs needed for adequate migraine control?
- ?Which specific alternative therapies have the strongest evidence when used alongside anti-CGRP monoclonal antibodies?
Trust & Context
- Key Stat:
- CGRP + PACAP targets Novel peptide-targeted therapies — CGRP antagonists (already approved) and PACAP antagonists (in development) — represent the most significant advance in migraine treatment, potentially complemented by alternative therapies
- Evidence Grade:
- Preliminary to moderate — individual CGRP-targeting drugs have strong clinical trial evidence, but the evidence for most complementary therapies and PACAP antagonists is still building.
- Study Age:
- Published in 2024, capturing the current state of both peptide-based and alternative migraine therapies.
- Original Title:
- New perspectives on migraine treatment: a review of the mechanisms and effects of complementary and alternative therapies.
- Published In:
- Frontiers in neurology, 15, 1372509 (2024)
- Authors:
- Song, Xiaoli(2), Zhu, Qian(2), Su, Lanqian, Shi, Lei, Chi, Hao, Yan, Yalan, Luo, Mei, Xu, Xibin, Liu, Baohong, Liu, Zhengyang, Yang, Jin
- Database ID:
- RPEP-09304
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are CGRP-targeting migraine drugs?
CGRP (calcitonin gene-related peptide) is a key molecule released during migraine attacks that causes blood vessel dilation and pain signaling. Drugs targeting CGRP — including monoclonal antibodies (erenumab, galcanezumab) and small molecule antagonists (rimegepant, ubrogepant) — block this process and have proven highly effective for both preventing and treating migraines.
Can acupuncture or supplements replace migraine medication?
For some patients with mild to moderate migraine, complementary therapies may provide adequate relief. However, for moderate to severe migraine, these approaches typically work best as additions to medical treatment rather than replacements. The strongest evidence supports acupuncture, magnesium supplementation, and riboflavin (vitamin B2) as helpful adjuncts.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09304APA
Song, Xiaoli; Zhu, Qian; Su, Lanqian; Shi, Lei; Chi, Hao; Yan, Yalan; Luo, Mei; Xu, Xibin; Liu, Baohong; Liu, Zhengyang; Yang, Jin. (2024). New perspectives on migraine treatment: a review of the mechanisms and effects of complementary and alternative therapies.. Frontiers in neurology, 15, 1372509. https://doi.org/10.3389/fneur.2024.1372509
MLA
Song, Xiaoli, et al. "New perspectives on migraine treatment: a review of the mechanisms and effects of complementary and alternative therapies.." Frontiers in neurology, 2024. https://doi.org/10.3389/fneur.2024.1372509
RethinkPeptides
RethinkPeptides Research Database. "New perspectives on migraine treatment: a review of the mech..." RPEP-09304. Retrieved from https://rethinkpeptides.com/research/song-2024-new-perspectives-on-migraine
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.